Tegoprubart Biosimilar – Anti-sCD40L mAb – Research Grade

Description of Tegoprubart Biosimilar - Anti-sCD40L mAb - Research Grade

Introduction:

Tegoprubart Biosimilar – Anti-sCD40L mAb is a research grade monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody targeting soluble CD40 ligand (sCD40L). This biosimilar has been designed to mimic the activity and structure of the original therapeutic antibody, while offering a more cost-effective option for researchers.

Structure:

Tegoprubart Biosimilar – Anti-sCD40L mAb is a recombinant, fully humanized monoclonal antibody that has been produced using advanced biotechnology techniques. It is composed of two heavy chains and two light chains, each consisting of variable and constant regions. The variable regions of the antibody are responsible for binding to the target molecule, sCD40L, while the constant regions provide stability and effector functions.

Activity:

The primary activity of Tegoprubart Biosimilar – Anti-sCD40L mAb is to bind to and neutralize sCD40L. This molecule is a cytokine that is involved in the activation and differentiation of various immune cells, including B cells, T cells, and dendritic cells. Overexpression of sCD40L has been linked to several inflammatory and autoimmune diseases, making it an important therapeutic target.

Tegoprubart Biosimilar – Anti-sCD40L mAb has been shown to effectively bind to sCD40L and block its activity, thereby preventing the activation of immune cells and reducing inflammation. This activity has been demonstrated in both in vitro and in vivo studies, making it a promising candidate for further research and potential clinical use.

Application:

As a research grade antibody, Tegoprubart Biosimilar – Anti-sCD40L mAb can be used in a variety of applications, including basic research, drug discovery, and preclinical studies. Its ability to specifically target sCD40L makes it a valuable tool for investigating the role of this cytokine in various diseases, as well as for screening potential therapeutic compounds that may target the sCD40L pathway.

In addition, Tegoprubart Biosimilar – Anti-sCD40L mAb can also be used in diagnostic assays to measure levels of sCD40L in patient samples. Elevated levels of sCD40L have been associated with diseases such as lupus, rheumatoid arthritis, and cardiovascular diseases, making this antibody a potential biomarker for these conditions.

Conclusion:

Tegoprubart Biosimilar – Anti-sCD40L mAb is a research grade monoclonal antibody that offers a cost-effective option for studying the role of sCD40L in various diseases. Its structure and activity have been designed to mimic the original therapeutic antibody, while providing a more affordable option for researchers. With its potential applications in basic research, drug discovery, and diagnostics, Tegoprubart Biosimilar – Anti-sCD40L mAb is a valuable tool for advancing our understanding of sCD40L and its role in disease pathogenesis.